Innoxel Lifesciences Pvt. Ltd. Successfully Completes U.S. FDA Inspection

Bharat Parenterals Limited is pleased to announce that its subsidiary, Innoxel Lifesciences Pvt. Ltd., has successfully cleared United States Food and Drug Administration (U.S. FDA) inspection at its manufacturing facility in Vadodara, Gujarat.

The inspection was conducted from April 28, 2025 to May 2, 2025 and concluded with the issuance of a single minor observation under Form 483.

This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence across its manufacturing operations. The successful completion of this inspection further strengthens the company's position in regulated markets and enhances its readiness to serve global customers with high-quality pharmaceutical products.

Shares of Bharat Parenterals Ltd was last trading in BSE at Rs. 987.90 as compared to the previous close of Rs. 940.90. The total number of shares traded during the day was 2061 in over 46 trades.

The stock hit an intraday high of Rs. 987.90 and intraday low of 940.90. The net turnover during the day was Rs. 2033988.00.

Source : Equity Bulls

Keywords

BharatParenterals INE365Y01019 Pharmaceuticals InnoxelLifesciences USFDA Inspection Vadodara Gujarat ManufacturingFacility